Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
Open Access
- 30 August 2022
- journal article
- research article
- Published by American Society for Microbiology in mBio
- Vol. 13 (4) , e0086922
Abstract
The recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.Keywords
Funding Information
- Pfizer
This publication has 54 references indexed in Scilit:
- The newly emerged SARS-Like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like proteaseProtein & Cell, 2013
- BIGSdb: Scalable analysis of bacterial genome variation at the population levelBMC Bioinformatics, 2010
- Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug DesignJournal of Virology, 2008
- The catalysis of the SARS 3C‐like protease is under extensive regulation by its extra domainThe FEBS Journal, 2006
- Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main ProteasesPLOS Biology, 2005
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transformNucleic Acids Research, 2002
- Helix cappingProtein Science, 1998
- Rules for α-Helix Termination by GlycineScience, 1994
- Basic local alignment search toolJournal of Molecular Biology, 1990